|Bid||12.21 x 1400|
|Ask||12.26 x 1400|
|Day's Range||11.93 - 12.32|
|52 Week Range||3.74 - 15.95|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.67|
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics first-quarter 2021 financial results conference call. With me is Dr. Todd Brady, president, and chief executive officer of Aldeyra. This morning we issued a press release reporting our financial results for the quarter ended March 31, 2021.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2021 and provided recent business highlights.
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 8:00 AM Eastern Time.